Expanding adjuvant therapy with ribociclib in HR-positive, HER2-negative early breast cancer
29 Jan 2026
byDr. Michael Untch, Helios Klinikum Berlin-Buch, Berlin, Germany
Despite advances in adjuvant endocrine therapy (ET), residual recurrence risk remains in patients with hormone receptor (HR)–positive, HER2-negative early breast cancer (eBC). At an industry-sponsored meeting, Professor Michael Untch of the Helios Klinikum Berlin-Buch in Berlin, Germany, and a panel of experts from Hong Kong discussed the survival benefits associated with adding ribociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor, to adjuvant ET in this patient population, and its implications in daily clinical practice.
